Ascend Wellness Holdings (AAWH) Asset Writedowns and Impairment (2021 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Asset Writedowns and Impairment came in at $744000.0 in Q1 2026, down 61.27% year-on-year from $1.9 million in Q1 2025, and down 71.16% quarter-over-quarter from $2.6 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
Ascend Wellness Holdings' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $744000.0 for Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 61.27% year-over-year to $744000.0 in Q1 2026; TTM through Mar 2026 was $15.7 million, a 57.1% increase from a year earlier, with the FY2025 full-year figure at $16.9 million, up 37.86% from the prior year.
- Asset Writedowns and Impairment slipped to $744000.0 in Q1 2026 per AAWH's latest filing, from $2.6 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $8.4 million in Q2 2023 and bottomed at $112000.0 in Q2 2022.
- The 5-year median for Asset Writedowns and Impairment is $4.2 million (2024), against an average of $4.0 million.
- Across the five-year window, Asset Writedowns and Impairment jumped 7442.86% in 2023 and slumped 86.96% in 2024, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $8.0 million in 2022, then sank by 53.86% to $3.7 million in 2023, then slumped by 86.96% to $484000.0 in 2024, then surged by 433.06% to $2.6 million in 2025, then sank by 71.16% to $744000.0 in 2026.
- Per Business Quant, the three latest AAWH Asset Writedowns and Impairment figures stand at $744000.0 (Q1 2026), $2.6 million (Q4 2025), and $7.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Ascend Wellness Holdings | 78.95 Mn | 18.03 Mn | 44.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 744,000.00 |
| Mar 31, 2026 | 744,000.00 |
| Dec 31, 2025 | 2.58 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 7.10 Mn |
| Sep 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | 5.28 Mn |
| Jun 30, 2025 | 5.28 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 484,000.00 |
| Dec 31, 2024 | 484,000.00 |
| Sep 30, 2024 | 4.46 Mn |
| Sep 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 3.71 Mn |
| Dec 31, 2023 | 3.71 Mn |